Nanobiotix S.A (NBTX) | Financial Analysis & Statements
Nanobiotix S.A. - ADR Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
67.8M
Total Liabilities
152.2M
Shareholders Equity
-84.5M
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
Nanobiotix S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 29.6M | -11.6M | 30.1M | 0 | 10.0K |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 23.1M | 40.5M | 38.4M | 32.6M | 30.4M |
| Selling, General & Administrative | 20.2M | 20.1M | 21.7M | 17.5M | 19.0M |
| Other Operating Expenses | -404.0K | -837.0K | 448.0K | 343.0K | 5.3M |
| Total Operating Expenses | 42.9M | 59.8M | 60.5M | 50.5M | 54.7M |
| Operating Income | -10.8M | -68.4M | -26.8M | -46.7M | -52.6M |
| Operating Margin % | -36.5% | 0.0% | -89.1% | 0.0% | -525,780.0% |
| Non-Operating Items | |||||
| Interest Income | 985.0K | 2.6M | 1.2M | 256.0K | 0 |
| Interest Expense | 10.4M | 8.1M | 8.0M | 5.8M | 671.0K |
| Other Non-Operating Income | -3.2M | 3.0M | -6.3M | 2.1M | 6.2M |
| Pre-tax Income | -24.0M | -68.0M | -39.6M | -57.0M | -47.0M |
| Income Tax | 3.0K | 101.0K | 120.0K | 10.0K | 5.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -24.0M | -68.1M | -39.7M | -57.0M | -47.0M |
| Net Margin % | -80.8% | 0.0% | -132.1% | 0.0% | -470,030.0% |
| Key Metrics | |||||
| EBITDA | -8.8M | -61.3M | -23.8M | -51.8M | -51.0M |
| EPS (Basic) | $-0.50 | $-1.44 | $-1.08 | $-1.64 | $-1.35 |
| EPS (Diluted) | $-0.50 | $-1.44 | $-1.08 | $-1.64 | $-1.35 |
| Basic Shares Outstanding | 47819627 | 47265189 | 36928161 | 34781098 | 31711436 |
| Diluted Shares Outstanding | 47819627 | 47265189 | 36928161 | 34781098 | 31711436 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Nanobiotix S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 52.8M | 49.7M | 75.3M | 41.4M | 83.9M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 2.1M | 3.0M | 905.0K | 101.0K | 0 |
| Inventory | - | - | - | - | - |
| Other Current Assets | 2.0K | -1.0K | 1.0K | 1.0K | - |
| Total Current Assets | 62.8M | 61.5M | 87.3M | 52.4M | 93.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.6M | 2.5M | 2.3M | 2.1M | 2.1M |
| Goodwill | 10.0K | 7.0K | 8.0K | 1.0K | 4.0K |
| Intangible Assets | 10.0K | 7.0K | 8.0K | 1.0K | 4.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 25.0K | - | - | - | - |
| Total Non-Current Assets | 5.0M | 6.0M | 6.6M | 7.4M | 8.7M |
| Total Assets | 67.8M | 67.4M | 93.9M | 59.8M | 101.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 6.6M | 4.5M | 6.7M | 4.0M | 5.0M |
| Short-term Debt | 4.3M | 4.9M | 5.0M | 4.6M | 8.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 312.0K | 7.8M | - | - | - |
| Total Current Liabilities | 57.5M | 58.9M | 49.9M | 37.9M | 36.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 91.0M | 46.0M | 45.5M | 48.6M | 37.8M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 3.2M | 27.8M | 2.0K | - | -1.0K |
| Total Non-Current Liabilities | 94.7M | 74.2M | 45.9M | 48.9M | 38.1M |
| Total Liabilities | 152.2M | 133.1M | 95.7M | 86.8M | 75.0M |
| Equity | |||||
| Common Stock | 1.5M | 1.4M | 1.4M | 1.0M | 1.0M |
| Retained Earnings | -24.0M | -68.1M | -39.7M | -57.0M | -47.0M |
| Treasury Stock | 228.0K | 228.0K | 228.0K | 228.0K | 202.0K |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -84.5M | -65.7M | -1.8M | -27.0M | 26.8M |
| Key Metrics | |||||
| Total Debt | 95.3M | 50.9M | 50.6M | 53.2M | 46.0M |
| Working Capital | 5.2M | 2.5M | 37.5M | 14.4M | 56.2M |
Balance Sheet Composition
Nanobiotix S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -24.0M | -68.1M | -39.7M | -57.0M | -47.0M |
| Depreciation & Amortization | 1.5M | 1.6M | 1.5M | 1.5M | 1.6M |
| Stock-Based Compensation | 3.5M | 4.3M | 3.2M | 3.2M | 3.2M |
| Working Capital Changes | 2.0M | 12.3M | 1.2M | -606.0K | 11.8M |
| Operating Cash Flow | -27.7M | -21.2M | -21.6M | -40.3M | -29.7M |
| Investing Activities | |||||
| Capital Expenditures | -538.0K | -846.0K | -328.0K | -92.0K | -228.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | -9.0K |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -538.0K | -846.0K | -328.0K | -91.0K | -237.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Debt Issuance | 42.9M | 0 | 150.0K | 0 | 0 |
| Debt Repayment | -4.7M | -4.2M | -3.8M | -4.7M | -3.7M |
| Financing Cash Flow | 38.9M | -4.2M | 53.7M | -4.7M | -4.1M |
| Free Cash Flow | -34.0M | -20.4M | -12.8M | -37.2M | -30.1M |
| Net Change in Cash | 10.7M | -26.2M | 31.8M | -45.1M | -34.1M |
Cash Flow Trend
Nanobiotix S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-67.61
Forward P/E
422.85
Price to Sales
45.83
PEG Ratio
422.85
Profitability Ratios
Profit Margin
-73.52%
Operating Margin
-196.42%
Return on Equity
28.36%
Return on Assets
-10.06%
Financial Health
Current Ratio
1.09
Debt to Equity
-1.33
Beta
0.55
Per Share Data
EPS (TTM)
$-0.59
Book Value per Share
$-1.65
Revenue per Share
$0.68
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| NBTX | 1.6B | -67.61 | - | 28.36% | -73.52% | -1.33 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






